TRT Over 65: Benefits, Risks, Dosing, and What the Evidence Actually Shows

Why Testosterone Levels Drop Differently After 65

Testosterone declines at roughly 1-2% per year after age 30, but the rate accelerates in men past 65 due to a combination of reduced Leydig cell mass, rising SHBG (which lowers free testosterone disproportionately), and blunted hypothalamic-pituitary responsiveness. The European Male Aging Study (N=3,369) found that symptomatic hypogonadism, defined by three sexual symptoms plus a total testosterone below 11 nmol/L (317 ng/dL), affected approximately 2.1% of men aged 40-79, rising steeply in the oldest cohort.

Free testosterone tells a sharper story. Because SHBG rises with age, a man of 68 may show a total testosterone of 320 ng/dL but a free testosterone below 50 pg/mL, a level associated with symptomatic fatigue, reduced bone mineral density, and sarcopenia. A 2020 analysis in the Journal of Clinical Endocrinology and Metabolism confirmed that calculated free testosterone below 64 pg/mL predicted hypogonadal symptoms more reliably than total testosterone alone in men over 60.

Two separate morning fasting draws are required before any prescription is written. A single low value on an afternoon sample is not a diagnosis. The Endocrine Society's 2018 Clinical Practice Guideline on Male Hypogonadism explicitly states: "We recommend against making a diagnosis of androgen deficiency in men who have not had at least 2 morning testosterone measurements that are clearly in the hypogonadal range."

What the Testosterone Trials Actually Found

The NIH-funded Testosterone Trials (TTrials) remain the most rigorous dataset on TRT specifically in men 65 and older. The coordinated group of seven trials enrolled 788 men (mean age 72) with total testosterone below 275 ng/dL and at least one qualifying symptom. Participants were randomized to testosterone gel 1% (target level 500 ng/dL) or placebo for 12 months. Published results across the TTrials consortium are available on PubMed.

The Sexual Function Trial showed that 56% of testosterone-treated men reported improved sexual activity compared with 38% in the placebo group (P<0.001). The Physical Function Trial found no significant improvement in the 6-minute walk test distance, which was the primary endpoint, though stair-climbing power improved modestly. Bone mineral density results were more striking: the Bone Trial documented a 3.4% increase in vertebral trabecular volumetric bone density and a 7.5% rise in bone strength by finite element analysis in the TRT arm versus placebo. The full Bone Trial report appeared in JAMA Internal Medicine in 2017.

Mood and cognition showed mixed results. The Vitality Trial found statistically significant but clinically modest improvements in fatigue and depressed mood. The Cognitive Function Trial found no significant benefit on memory or executive function at 12 months.

The TTrials were not powered to detect cardiovascular events. Coronary artery non-calcified plaque volume increased more in the TRT arm than placebo, a finding published in JAMA that generated caution without providing definitive evidence of harm.

The TRAVERSE Trial and Cardiovascular Risk

TRAVERSE (N=5,246, mean age 63, follow-up 33 months) was designed specifically to test cardiovascular safety. Men with hypogonadism and pre-existing cardiovascular disease or elevated 10-year risk were randomized to testosterone 1.62% gel or placebo. The primary MACE results published in the New England Journal of Medicine in 2023 showed that TRT was noninferior to placebo for major adverse cardiovascular events (7.0% vs. 7.3%).

The finding that generated the most regulatory attention was atrial fibrillation: AF occurred in 3.5% of the testosterone group versus 2.4% placebo (P=0.02). The FDA updated the testosterone label in 2024 to include AF as a risk requiring patient counseling. For men over 65 with existing AF, paroxysmal AF, or CHA2DS2-VASc scores above 2, the benefit-risk calculation shifts and prescribers should document that discussion explicitly.

Acute kidney injury and pulmonary embolism rates were not significantly different between arms. The trial population skewed toward men at elevated baseline cardiovascular risk, so results may not generalize to a healthy 66-year-old with no prior cardiac history and a single low testosterone draw.

Hematologic Monitoring: The Risk Most Patients Underestimate

Testosterone stimulates erythropoiesis through EPO-dependent and EPO-independent pathways. In the TTrials, polycythemia (hematocrit above 54%) occurred in 5.9% of the testosterone arm versus 0% in placebo. A systematic review in the Annals of Internal Medicine confirmed that injectable testosterone formulations carry higher polycythemia rates than transdermal preparations, likely because of peak supraphysiologic levels after injection.

Practical protocol: Check a CBC at baseline, at 3 months, and every 6 months thereafter. If hematocrit exceeds 54%, suspend TRT until it falls below 50%, evaluate for secondary erythrocytosis, and consider switching from injectable to transdermal if reinitiation is planned. Men who already have borderline hematocrit at baseline (50-53%) should start on a transdermal formulation rather than injections. The Endocrine Society guideline sets 54% as the threshold for dose reduction or discontinuation.

How Dosing Differs From Younger Men

Older men generally require lower doses to reach the same serum target, and the therapeutic window is narrower. A 40-year-old might tolerate 100-150 mg of testosterone cypionate weekly and land at 600 ng/dL trough; the same dose in a 70-year-old may push hematocrit above 54% or drive dihydrotestosterone (DHT) to levels that accelerate benign prostatic hyperplasia symptoms.

Starting doses for men over 65 at HealthRX follow a conservative titration:

• Testosterone cypionate or enanthate: 50 mg IM weekly (not 200 mg every two weeks, which creates peaks and troughs that increase erythrocytosis risk). Titrate by 10-20 mg increments after 6-week steady-state labs.
• Testosterone gel 1.62% (AndroGel): 40.5 mg (one pump) applied to shoulders daily. Titrate to 81 mg if trough testosterone remains below 350 ng/dL at week 6.
• Transdermal patch (Androderm): 2 mg nightly, titrating to 4 mg if tolerated and serum levels remain sub-therapeutic.
• Testosterone pellets (Testopel): Generally avoided as a first-line choice in men over 65 because dose adjustment is impossible once implanted and polycythemia requires waiting for pellet resorption.

Target serum levels for men over 65 should sit in the mid-normal range: 400-550 ng/dL total testosterone, with free testosterone 80-150 pg/mL. Supraphysiologic targets (above 800 ng/dL) have no established additional benefit and increase erythrocytosis and PSA-related risk. Data from the Baltimore Longitudinal Study of Aging suggest that total testosterone in the 400-600 ng/dL range corresponds to functional benefits with an acceptable safety profile in older men.

TRT Over 65 vs. TRT in Younger Men (Ages 30-50)

The underlying indication differs by age. Men under 50 with hypogonadism most commonly have either primary testicular failure (elevated LH/FSH) or secondary hypogonadism from obesity, opioid use, or pituitary pathology. Secondary hypogonadism from excess adiposity is particularly reversible: a 10% reduction in body weight can raise testosterone by 60-100 ng/dL in obese men without any exogenous hormone.

Fertility preservation is a major differentiator. Exogenous testosterone suppresses LH and FSH, reducing intratesticular testosterone and halting spermatogenesis within 6-12 weeks in most men. A 1996 WHO multicenter trial using testosterone enanthate 200 mg weekly achieved azoospermia in 71% of participants, confirming TRT's contraceptive effect. For a 35-year-old who may want biological children, clomiphene citrate 25-50 mg every other day or enclomiphene preserves the hypothalamic-pituitary-gonadal axis while raising testosterone. For a 67-year-old, fertility is rarely the clinical question, though the conversation should still appear in the chart.

Men aged 50-65 occupy an intermediate position. The Hypogonadism in Males (HIM) study of 2,162 men in primary care found hypogonadism prevalence of 38.7% in men over 45, with obesity and type 2 diabetes as the strongest predictors. In this cohort, addressing metabolic drivers first often corrected testosterone without prescribing TRT. Over 65, metabolic intervention alone rarely restores testosterone to symptomatic-relief thresholds because Leydig cell mass has irreversibly declined.

Cardiovascular monitoring intensity also scales with age. A 38-year-old on TRT needs a hematocrit check at 3 and 6 months, then annually. A 68-year-old needs the same cadence for CBC plus a lipid panel (testosterone lowers HDL modestly at higher doses), a PSA, a blood pressure reading, and at minimum a symptom review for AF, lower urinary tract symptoms, and sleep apnea exacerbation.

PSA and Prostate Monitoring in Men Over 65

Active prostate cancer is an absolute contraindication to TRT. The concern about TRT and prostate cancer stems from the androgen-dependence of most prostate cancers established by Huggins and Hodges in 1941 and confirmed repeatedly since. A 2015 systematic review in the European Urology journal found no statistically significant increase in prostate cancer incidence with TRT, though follow-up periods averaged only 2-3 years, which is insufficient for slow-growing tumors.

The Endocrine Society recommends PSA at 3-6 months after starting TRT, then annually. A confirmed rise of more than 1.4 ng/mL above baseline within a 12-month period warrants urologic referral regardless of absolute PSA value. This threshold comes from the 2018 guideline. Men with baseline PSA above 4 ng/mL or above 3 ng/mL with a first-degree relative with prostate cancer should complete a urologic evaluation before TRT begins, not after.

Lower urinary tract symptoms (LUTS) driven by benign prostatic hyperplasia may worsen modestly with TRT because DHT mediates prostatic growth. Baseline IPSS (International Prostate Symptom Score) documentation is standard practice. An IPSS above 19 (severe symptoms) at baseline is a relative contraindication; an alpha-blocker or 5-alpha reductase inhibitor may need to be added or optimized before starting TRT.

TRT for Elite Athletes and WADA Regulations

Men over 65 who compete in masters athletics face a hard regulatory line: WADA's Prohibited List classifies all exogenous testosterone under S1 Anabolic Agents, prohibited at all times in sanctioned competition, regardless of medical necessity.

A Therapeutic Use Exemption (TUE) application requires documentation of confirmed hypogonadism (two testosterone measurements below the laboratory reference range, pituitary imaging if secondary, and documented symptoms), evidence that the condition is not the result of prior prohibited substance use, and confirmation that no permitted alternative exists. The WADA TUE guidelines note that TUEs for testosterone are among the most scrutinized applications because of the performance advantage at any age.

Practically, a 67-year-old masters triathlete with documented Klinefelter syndrome or post-orchiectomy hypogonadism has a stronger TUE case than a 68-year-old with age-related decline and a testosterone of 280 ng/dL. The distinction matters because anti-doping tribunals look at whether the condition is primary (gonadal failure) or age-related decline in otherwise intact men.

TRT and Bodybuilding Use vs. Medical TRT

The term "TRT" is used loosely in bodybuilding communities to describe testosterone doses that often exceed 200-400 mg per week, producing testosterone levels well above 1 to 000 ng/dL. Medical TRT aims for the mid-normal physiologic range (300-700 ng/dL per the Endocrine Society reference). The distinction is not semantic. A 2021 study in the Journal of the American Heart Association found that non-prescribed supraphysiologic androgen use was associated with left ventricular hypertrophy, reduced diastolic function, and coronary artery calcification scores roughly 2.5-fold higher than age-matched controls.

For men over 65 who present having used bodybuilding-level testosterone doses for years, the clinical picture includes suppressed or absent LH/FSH, possible testicular atrophy, elevated hematocrit, and in many cases, a need for post-cycle assessment rather than straightforward TRT initiation. An hCG stimulation test (2 to 500 IU IM and testosterone measured at 72 hours) can help distinguish residual Leydig cell function from permanent primary failure after prolonged exogenous androgen exposure. Reference ranges and protocol details are available through the NIH endocrinology resources.

Sleep Apnea: The Contraindication Clinicians Miss

Obstructive sleep apnea (OSA) is both a cause and a consequence of hypogonadism in older men, and TRT can worsen it. A randomized crossover trial published in the Journal of Clinical Endocrinology and Metabolism showed that testosterone administration to eugonadal men doubled the apnea-hypopnea index during REM sleep. In men already using CPAP therapy with well-controlled OSA, TRT can generally proceed with monitoring; in men with undiagnosed or undertreated OSA, TRT should wait until sleep testing and, if indicated, CPAP titration are completed.

An Epworth Sleepiness Scale score above 10 at intake, witnessed apneas, or a neck circumference above 17 inches in a symptomatic man should trigger a sleep study referral before TRT initiation. The AASM recommends formal polysomnography or a validated home sleep apnea test as the diagnostic standard. Current AASM diagnostic and treatment guidelines can be reviewed at the NCBI bookshelf.

The 6-Month Decision Point

Most men over 65 who start TRT can expect a staged response. Sexual function and energy improvements, if they occur, generally appear within 3-6 weeks of achieving target serum levels. Body composition changes, specifically lean mass gain and fat mass reduction, require 3-6 months of consistent therapy. Bone density improvements require at least 12 months and are best tracked with dual-energy X-ray absorptiometry (DEXA) at baseline and 12 months. A 2006 meta-analysis in the Journal of Clinical Endocrinology and Metabolism pooled data from 51 trials and found that TRT increased lumbar spine BMD by a mean of 3.7% and femoral neck BMD by 1.5% versus placebo across all age groups.

At 6 months, if a patient reports no subjective improvement in any of the three symptom domains (sexual function, energy, mood) and labs confirm testosterone in the 400-550 ng/dL range, continuing TRT requires a frank re-evaluation. The Endocrine Society guideline states: "We suggest reassessing whether the patient has hypogonadism and whether TRT is providing benefit in men who have not had a satisfactory response after 3-6 months of treatment."

Discontinuation after a failed trial does not require a taper. Endogenous production in an older man is already suppressed and will return to its pre-treatment baseline, typically within 3-6 months of stopping, though men with pre-existing secondary hypogonadism may recover faster than those with primary gonadal failure.

Complete Monitoring Schedule for Men Over 65 on TRT

The following cadence reflects Endocrine Society and American Urological Association guidance for this age group:

Baseline (before first dose): Total testosterone (two fasting morning draws, at least one week apart), free testosterone, LH, FSH, complete blood count, comprehensive metabolic panel, PSA, IPSS questionnaire, DEXA (if baseline osteopenia/osteoporosis suspected), Epworth Sleepiness Scale, blood pressure, and body weight. Baseline workup recommendations are detailed in the AUA hypogonadism guideline.

Week 6: Total and free testosterone (trough if injectable, 2 hours post-application if transdermal), hematocrit, blood pressure. Adjust dose toward 400-550 ng/dL target.

Month 3: Full repeat of testosterone levels, CBC, PSA, symptom review, blood pressure.

Month 6 and annually thereafter: All above plus lipid panel, metabolic panel, DEXA at 12 and 24 months, repeat IPSS if LUTS were present at baseline.

The CDC's data on osteoporosis and bone health in older adults supports dual-endpoint monitoring for both fracture risk and testosterone status, since the two conditions frequently coexist in men over 65.

A PSA rise above 1.4 ng/mL in any 12-month window, a hematocrit above 54%, a new diagnosis of AF, or worsening sleep apnea are each independent reasons to pause TRT, investigate, and only restart after a documented benefit-risk discussion recorded in the chart.